1. Home
  2. WTO vs KZIA Comparison

WTO vs KZIA Comparison

Compare WTO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WTO

UTime Limited

HOLD

Current Price

$0.67

Market Cap

2.4M

Sector

Technology

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.81

Market Cap

161.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTO
KZIA
Founded
2008
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
161.5M
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
WTO
KZIA
Price
$0.67
$7.81
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$17.67
AVG Volume (30 Days)
273.8K
284.5K
Earning Date
01-02-2026
12-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,589,265.00
$1,199,108.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
54.01
N/A
52 Week Low
$0.65
$2.86
52 Week High
$440.00
$17.40

Technical Indicators

Market Signals
Indicator
WTO
KZIA
Relative Strength Index (RSI) 44.01 42.71
Support Level $0.80 $8.91
Resistance Level $1.25 $11.06
Average True Range (ATR) 0.10 2.23
MACD -0.07 -0.54
Stochastic Oscillator 9.10 15.07

Price Performance

Historical Comparison
WTO
KZIA

About WTO UTime Limited

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: